article · RSC Advances

Anticancer evaluations of iodoquinazoline substituted with allyl and/or benzyl as dual inhibitors of EGFR <sup>WT</sup> and EGFR <sup>T790M</sup> : design, synthesis, ADMET and molecular docking

Ahmed K. B. Aljohani
Ahmed El-morsy
Basmah Almohaywi
Felemban Athary Abdulhaleem M
Hanan E. Osman
Omar M. Alatawi
Hussam Y. Alharbi
Khaled El‐Adl
Sara A. Almadani
Marwa Alsulaimany
Majed S. Aljohani
Samy Mohamady

20246 citationsOpen accessBritish University in Egypt

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

Fifteen new iodoquinazoline derivatives, 5a,b to 18, are reported in this study and their anticancer evaluation as dual inhibitors of EGFR WT and EGFR T790M .

Research topics

Lung Cancer Treatments and Mutations
Cancer therapeutics and mechanisms
Quinazolinone synthesis and applications

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1039/d4ra00502c

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.